Baseline Characteristics of Patients Included in Study
| Patient no. | Age (y) | Sex | Histology | PD-L1 TPS (%) | PD-L1 CPS (%) | Treatment cycles (n) | BOR | Reason for treatment discontinuation | PFS (d) | OS (d) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 59 | F | Adenocarcinoma | 0 | 12.5 | 7 | SD | PD | 86 | 823 |
| 2 | 53 | M | Adenocarcinoma | 0 | 0 | 1 | PD | PD | 19 | 19 |
| 3 | 75 | F | Adenocarcinoma | 0 | 7,5 | 1 | PD | PD | <15 | 63 |
| 4 | 79 | M | Adenocarcinoma | 100 | 100 | 2 | PD | PD | 34 | 40 |
| 5 | 77 | M | Adenocarcinoma | 0 | 5 | 2 | PD | PD | 22 | 147 |
| 6 | 57 | F | Squamous cell carcinoma | 1 | 5 | 10 | SD | PD | 154 | 182 |
| 7 | 54 | M | Adenocarcinoma | 100 | 90 | 14 | PR | PD | 183 | NR |
| 8 | 70 | M | Squamous cell carcinoma | NE | NE | 9 | PR | Toxicity | 684 | NR |
| 9 | 70 | M | Adenocarcinoma | 0* | NE | 1 | PD | PD | 9 | 15 |
| 10 | 64 | M | Adenocarcinoma | 0 | 0 | 1 | PD | PD | 2 | 2 |
| 11 | 72 | M | Adenocarcinoma | 1 | 25 | 22 | NE | COVID-19 pandemic | NR | NR |
| 12 | 72 | F | Not otherwise specified | 100 | 90 | 12 | PR | Toxicity | NR | NR |
| 13 | 69 | M | Squamous cell carcinoma | 0 | 0 | 3 | PD | PD | 41 | 78 |
* PD-L1 TPS derived from cytology.
BOR = best observed response; SD = stable disease; PD = progressive disease; NR = not reached; NE = not evaluable; PR = partial response.